跳至主要内容
临床试验/EUCTR2010-024211-13-ES
EUCTR2010-024211-13-ES进行中(未招募)1 期

ong term, single-arm, open-label extension study of the MUSIC study toassess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC O

ACTELION Pharmaceuticals Ltd.0 个研究点目标入组 178 人开始时间: 2011年11月10日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
178

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Signed informed consent prior to initiation of any study-related
  • - Patients with IPF and having completed the double-blind AC-
  • 055B201/MUSIC study as scheduled, i.e., having remained in the study
  • until the sponsor-declared end-of study, whether or not study treatment
  • was prematurely discontinued.
  • - Women of childbearing potential must have a negative pre-treatment
  • serum pregnancy test and must use a reliable method of contraception
  • during study treatment and for at least 28 days after study treatment
  • termination.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 65
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 113

排除标准

  • - Any major violation of protocol AC-055B201/MUSIC.
  • - Premature discontinuation of study treatment during the AC-
  • 055B201/MUSIC study due to an adverse event (AE) assessed as related
  • to the use of macitentan, excluding events of IPF worsening.
  • - Pregnancy or breast-feeding.
  • - AST and/or ALT > 3 times the upper limit of the normal range.
  • - Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug
  • or alcohol dependence or psychiatric disease.
  • - Known hypersensitivity to drugs of the same class as macitentan, or
  • any of the excipients.

研究者

相似试验

进行中(未招募)
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeMedDRA version: 17.1Level: PTClassification code 10058554Term: Eisenmenger's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEisenmenger Syndrome
EUCTR2012-004411-31-ROActelion Pharmaceuticals Ltd.217
进行中(未招募)
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeMedDRA version: 20.0 Level: LLT Classification code 10058554 Term: Eisenmenger's syndrome System Organ Class: 100000164933Eisenmenger Syndrome
EUCTR2012-004411-31-GBActelion Pharmaceuticals Ltd217
进行中(未招募)
1 期
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC studyPatients with Idiopathic Pulmonary FibrosisMedDRA version: 13.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2010-024211-13-SEACTELION Pharmaceuticals Ltd.178
进行中(未招募)
1 期
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC studyPatients with Idiopathic Pulmonary FibrosisMedDRA version: 14.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2010-024211-13-SIACTELION Pharmaceuticals Ltd.178
进行中(未招募)
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeEisenmenger Syndrome
EUCTR2012-004411-31-PLActelion Pharmaceuticals Ltd.220